Recruiting
Not applicable
POTS-FLOW: Interplay Between Gut Hormones and Autonomic Postprandial Blood Flow Regulation in Patients With POTS
Condition(s) studied
Postural Orthostatic Tachycardia Syndrome (POTS)Healthy
Investigational drug(s) / intervention(s)
Saline/PlaceboGIPR antagonistGLP-1R antagonistCCK agonist
Saline/Placebo: NaCl(9mg/ml)
GIPR antagonist: GIP(3-30)NH2
GLP-1R antagonist: GLP-1(9-39)NH2
CCK agonist: CCK-8
Study summary
This study will describe the interplay between the gut hormones GIP and CCK and their regulation of blood flow to the large vessels in patients with Postural Orthostatic Tachycardia Syndrome (POTS) and GIP, CCK and GLP-1 in healthy. This is addressed by hormone infusions during MR-scans of the abdomen and intake of oral glucose.
Eligibility
Inclusion Criteria POTS patients:
* Previously diagnosed with POTS in tilt test or active stand-test (either newly diagnosed within last 3 months or in new tilt test/active stand test during screenings visit)
* Reproducible orthostatic intolerance with raise in HR on \>30 bpm when standing within 10 minutes of change of supine to standing in age \>19 years or \>40 bpm in age 18-19 years.
* POTS symptoms/orthostatic intolerance
* Age 18-50
* Waist ratio \<180 cm
Exclusion Criteria:
* Chronic illness
* Metallic implants
* Above 10 alcoholic drinks or week or substance abuse
* Other types of sinus tachycardia or heart disease
* Liverenzymes two times above normal values
* Decreased kidney function eGFR \<90 or elevated kreatinkinasis
* Thyroid disease or TSH out of reference
* Uncontrollable low or high blood pressure
* Blood vessels that cannot be visualized on MR
* Any disease that might influence the health of the participant during the study or participants that receives medicine that cannot be paused for 36 hours
Inclusion Criteria:
* Age 18-50
* Waist ratio \<180 cm
* Matched a POTS patient in age, sex and BMI
Exclusion Criteria:
* Chronic illness
* Metallic implants
* Above 10 alcoholic drinks or week or substance abuse
* POTS; other types of sinus tachycardia or heart disease
* Liverenzymes two times above normal values
* Decreased kidney function eGFR \<90 or elevated kreatinkinasis
* Thyroid disease or TSH out of reference
* Uncontrollable low or high blood pressure, Orthostatic hypotension
* Blood vessels that cannot be visualized on MR
* Any disease that might influence the health of the participant during the study or participants that receives medicine that cannot be paused for 36 hours
Primary outcome measure(s)
- Redistribution of splanchnic blood flow in the vessel mesenteric superior artery (MR) — Continuously for 80 minutes/during infusions
Blood flow in the superior mesenteric artery measured with MR ml/min
Trial sites (1)
| Facility | City | Region | Status |
| Rigshospitalet |
Copenhagen |
Denmark |
Recruiting |
More University of Copenhagen trials in Denmark
Other trials for the same condition